On June 26, 2019 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is reported the acceptance of two oral presentations and five poster presentations at the International Society of Pediatric Oncology (SIOP) Annual Congress held October 23 through October 26, 2019 in Lyon, France (Press release, Y-mAbs Therapeutics, JUN 26, 2019, View Source [SID1234537276]). The abstracts for oral presentations are publicly available online at View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstracts include the following presentation of omburtamab, one of the Company’s lead product candidates, which is currently being evaluated for the treatment of patients with CNS/Leptomeningeal metastasis from neuroblastoma, diffuse intrinsic pontine glioma ("DIPG"), and desmoplastic small round cell tumors ("DSRCT"):
"A curative approach to central nervous system metastatis of neuroblastoma," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (oral presentation)
The abstracts also include the following presentations of naxitamab, the Company’s second lead product candidate, which is currently being evaluated for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma, osteosarcoma and other GD2-positive tumors:
"Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of "HITS" pilot/phase II study," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (oral presentation)
"Preliminary tolerability assessment of naxitamab (humanized anti-GD-2 monoclonal antibody) therapy in a phase 2 osteosarcoma trial," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (poster presentation)
"High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for consolidating ≥2nd complete remission of high-risk neuroblastoma," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (poster presentation)
"High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for neuroblastoma: Outpatient treatent low immunogenicity, and major responses in a Phase II trial," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (poster presentation)
"High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for relapsed neuroblastoma resistant to salvage therapy: A Phase II trial," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (poster presentation)
"High-dose naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for high-risk neuroblastoma: Efficacy against histologically-evident primary refractory metastases in bone marrow," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (poster presentation)